SCHEMBL7737830

SCHEMBL7737830

CCCCn1ccc(-c2cccc(OC)c2)c(C(=O)OCC)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.49
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 6/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 2/20 0.45
THRB P10828 1/20 0.45
NPSR1 Q6W5P4 1/20 0.43
ICMT O60725 2/20 0.42
BRD4 O60885 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.41
TLR8 Q9NR97 1/20 0.41
PPARG P37231 1/20 0.41
CNR2 P34972 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
PTPN1 P18031 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7735824 0.88 GRM2 (0.49) GRM2KDM4EHSD17B10ICMTBRD4
SCHEMBL7737831 0.87 ALDH1A1 (0.51) GRM2ALDH1A1KDM4EHPGDTP53
SCHEMBL7735825 0.74 GFER (0.48) GRM2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL7726333 0.74 LPAR1 (0.47) GRM2
SCHEMBL7735517 0.73 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL7725862 0.73 BRD4 (0.39) GRM2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5885102 0.72 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL7735514 0.71 ACAT1 (0.50) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL10362785 0.70 KDM4E (0.65) ALDH1A1KDM4EHPGDMAPTNPSR1
SCHEMBL7710797 0.70 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK GRM2 3251/4885ALDH1A1 716/4885KDM4E 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.